Brochier M, Raynaud R, Planiol T, Fauchier J P, Griguer P, Archambaud D, Pellois A, Clisson M
Arch Mal Coeur Vaiss. 1975 Jun;68(6):563-9.
Two randomized series of 60 cases of myocardial infarction or menace syndrome have been treated at the acute stage, one by Heparin alone, the other by the combination Urokinase-Heparin. The average dosage was 300 mg Heparin in the first series, of 2,700,000 CTA units of Urokinase combined with 240 mg of Heparin in the second series. After the first 24 hours, equal heparinization was performed in both series up to the third week. Significantly different results were obtained in the two series. They favour Urokinase and concern: -- the disappearance time of pain, -- the course of the arrhythmias and of cardiac failure, -- the regression or limitation of the necrosis q waves and the lesion areas on the electrocardiogram. Finally the 30th-day overall mortality was 13% in the Heparin series and 3% in the myocardial infarction on the way of constitution, or which have done so for less than 24 hours.
对两个各有60例心肌梗死或先兆综合征患者的随机系列进行了急性期治疗，一组仅用肝素治疗，另一组用尿激酶 - 肝素联合治疗。第一组肝素平均剂量为300毫克，第二组尿激酶剂量为270万CTA单位并联合240毫克肝素。最初24小时后，两组均进行同等肝素化直至第三周。两组获得了显著不同的结果。这些结果有利于尿激酶，涉及：——疼痛消失时间，——心律失常和心力衰竭的病程，——心电图上坏死性q波和病变区域的消退或局限。最后，肝素组第30天的总死亡率为13%，而处于发病过程中或发病不到24小时的心肌梗死患者组为3%。
